Lumea Digital Pathology

by Lumea  · Based in United States → — Integrated Diagnostics Built for Human Impact
Dermatology Oncology Pathology
Website
Claim this tool
Is this the maker? Claim the company →

Overview

Lumea is a specialty-specific digital pathology platform that covers the entire diagnostic workflow, from biopsy to final report. The platform has four core components: tissue-handling and histology technology (BxBoard, BxChip, BxCamera) to improve specimen quality and workflow efficiency; an FDA-cleared digital pathology viewer (Viewer+) for full diagnostic capability on any device from any location; BxLink, an all-in-one digital pathology-enabled LIS for complete case management and molecular test ordering; and an open AI ecosystem that allows labs to integrate best-in-class AI tools from partners like Paige, Primaa, and Mindpeak directly into their diagnostic workspace.

Lumea aims to provide a connected, FDA-cleared digital pathology workflow that delivers faster turnaround, greater diagnostic confidence, and improved experiences for technicians, pathologists, and patients.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Tissue-handling and histology technology (BxBoard, BxChip, BxCamera)
  • FDA-cleared digital pathology viewer (Viewer+)
  • Digital pathology-enabled LIS (BxLink)
  • Open AI ecosystem with integrated partner AI tools (e.g., Paige, Mindpeak)
  • Single-screen diagnostic workspace
  • Lightning-fast image rendering
  • One-click molecular ordering
  • Intelligent personalization of reporting preferences
  • Remote diagnosis and teleconsultation capabilities
  • Permanent, searchable digital archive

Use Cases

  • Primary diagnosis from digital images
  • Teleconsultation and second opinions
  • AI-assisted analysis and tumor boards
  • Medical education and research
  • Remote sign-out with work-from-home capabilities
  • Improved molecular test utilization

What Physicians Need to Know

Evidence Base
Lumea's platform is designed to meet stringent clinical validation requirements for surgical pathology and has received FDA 510(k) clearance for primary clinical diagnosis. The platform integrates AI tools from partners like Paige, Primaa, and Mindpeak, which are often FDA-cleared for specific applications such as prostate cancer Gleason grading and lymph node metastasis detection. Lumea's approach also includes pre-analytical innovations like BxBoards and BxChips, with research demonstrating their impact on tissue quality, cancer detection rates, and reduction in fragmentation.
Clinical Validation Studies
Lumea's platform has received FDA 510(k) clearance for primary clinical diagnosis, which requires demonstrated equivalence to traditional methods. Multiple peer-reviewed studies have shown diagnostic concordance between digital and glass slide pathology to be equivalent, and in some applications with AI assistance, digital pathology has shown improved accuracy. Lumea's solutions have been associated with a 9.3% increase in cancer detection rates and a 50% reduction in diagnostic time for prostate biopsy cases. Their tissue-handling technology has also been shown to increase cancer detection rates by 19% and reduce tissue fragmentation by 35%.
Alert Fatigue Management
While Lumea's platform integrates AI assistants into the workflow, the information available does not specifically detail proprietary alert fatigue management strategies. However, the platform's design focuses on a unified diagnostic suite to reduce fragmented workflows and multiple logins, which are common contributors to alert fatigue in other systems. The integration of AI is intended to assist pathologists and reduce cognitive load, rather than create additional burdens.
Differential Diagnosis Support
Lumea's platform supports differential diagnosis through its integrated AI ecosystem, allowing pathologists seamless access to various AI tools from partners. These AI tools can assist in identifying abnormalities and quantifying features. Additionally, the platform's ability to display multiple section levels and various special stains simultaneously on one screen enhances the pathologist's ability to review and compare, aiding in differential diagnosis.
Guideline Update Frequency
Lumea has integrated Alpine Path, an AI platform from TreatmentGPS, which provides guideline-based treatment guidance directly into pathology reports. This integration generates structured clinical summaries aligned with current NCCN guidelines for prostate and bladder cancer, including risk stratification, ancillary testing considerations, and treatment considerations. The frequency of updates for these guidelines within the Alpine Path integration would depend on TreatmentGPS's maintenance of NCCN guidelines.
Clinical Workflow Integration
Lumea offers a unified diagnostic suite that replaces fragmented viewers, LIS, AI, and molecular test ordering with a single-screen workspace. This integration links slides, patient identity, reporting, billing, and case status, eliminating multiple logins and window switching. The platform embeds AI assistants directly into workflow automation and quality control within the viewer, providing seamless access to an AI marketplace. It also enables one-click molecular ordering and tracking directly within the viewer, which can deliver results up to 60% faster. Lumea's BxLink platform is a digital pathology-enabled LIS for complete case management and molecular test ordering, and it also integrates with third-party LIS platforms.
Decision Audit Trail
The digital nature of Lumea's workflow ensures a robust audit trail. The system is designed with access control and audit trails to comply with CAP/CLIA requirements, providing a complete audit log.
Physician Tip

Leverage Lumea's unified diagnostic suite to minimize context switching and streamline your workflow, as it integrates image viewing, case management, AI results, and molecular test ordering on a single screen. Utilize the integrated AI tools as a 'second set of eyes' for tumor detection and as a QA/QC tool to enhance diagnostic confidence and efficiency. Take advantage of the one-click molecular ordering directly within the viewer to ensure appropriate ancillary tests are ordered promptly, leading to faster treatment decisions. Explore the specialty-specific solutions and integrated AI tools, particularly for urology, dermatopathology, and gastroenterology, to optimize your diagnostic process for high-volume cases. The Alpine Path integration can provide guideline-based treatment guidance directly in pathology reports, offering a concise reference for NCCN-based risk stratification and treatment considerations.

Lumea's platform is designed for extensive integration, offering an open AI ecosystem that allows labs to integrate leading computational pathology tools from partners like Paige, Primaa, Mindpeak, and AIRA Matrix directly into the diagnostic workspace. It provides deep LIS integration, with BxLink functioning as a digital pathology-enabled LIS, and also integrates with third-party LIS platforms. The system supports seamless integration with Electronic Medical Record (EMR) systems for simplified report retrieval and information sharing. Lumea's tissue-handling technology, such as the BxBoard, is also being integrated into grossing stations like the Mopec Maestro Encore, bridging pre-analytical processes with digital pathology workflows. Furthermore, Lumea integrates molecular and ancillary testing directly into the viewer, eliminating the need for separate portals or LIS for ordering and tracking.

Details

Category Clinical Decision Support & Reference, Oncology AI, Pathology AI
Pricing Unknown — Multiple options for leasing, purchasing, or pay-on-demand commercial agreements are available.
DeploymentCloud-based, with on-premise infrastructure requirements for scanners and storage.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status Unknown AI-estimated

Lumea's Viewer+ software received FDA 510(k) clearance (K242244) in March 2025 for primary clinical diagnosis. It is cleared for clinical use with the Hamamatsu NanoZoomer S360MD whole slide scanner and the Barco MDPC-8127 monitor in the United States.
Integrations
EHR Not specified
Specialties Dermatology, Oncology, Pathology

What the Web Says

Lumea Digital Pathology offers a comprehensive digital pathology platform that aims to improve efficiency, accuracy, and patient care in pathology labs. It integrates tissue-handling technology with AI-driven workflows and a digital viewer, allowing for faster diagnoses, enhanced collaboration, and better management of cases. The platform has received FDA 510(k) clearance for its Viewer+ software for primary diagnosis in clinical settings.

Overall: Positive

Strengths

  • Improved efficiency and faster turnaround times for diagnoses, with documented reductions in lab time and ancillary test turnaround.
  • Enhanced diagnostic accuracy through AI-assisted analysis tools and improved tissue specimen quality from collection to diagnosis.
  • Streamlined remote consultations and easier access to second opinions, overcoming geographical barriers.
  • Integrated workflow with image viewing, case management, AI results, and report generation all on one screen, reducing the need to switch between multiple systems.
  • Scanner-agnostic platform, supporting images from various major scanner manufacturers.
  • Reduced tissue handling errors, physical storage needs, and potential for mislabeling or loss of slides.

Limitations

  • Initial capital costs for hardware and software can be significant.
  • Labor costs associated with training staff and maintaining the digital infrastructure.
  • Data storage costs, especially for large volumes of digital pathology data.
  • Integration, validation, and compliance with regulatory standards can require significant time and resources.
  • Potential for a temporary increase in workload during the initial validation phase as pathologists learn new systems.
  • Some users on Reddit express concerns about the cost of digital pathology solutions making them inaccessible for smaller independent groups, and the potential for AI to devalue the work of pathologists if not implemented ethically.

Based on reviews from: Lumea Digital Pathology Customer Stories, Lumea Digital Pathology Blog, VayoMed, EINPresswire.com, Digital Pathology Place, Reddit

Last updated: 2026-09-11

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Lumea Digital Pathology

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Lumea Digital Pathology
Lumea integrates Alpine Path for AI-powered treatment guidance in digital pathology
Lumea has integrated Alpine Path into its digital pathology workflow, partnering with TreatmentGPS to provide guideline-based clinical decision support directly within pathology reports. This integration aims to streamline treatment guidance by generating structured clinical summaries, including NCCN-based risk stratification and ancillary testing considerations.
2026-09
Lumea Digital Pathology
Lumea and Paige Partner to Advance AI-Powered Digital Pathology
Lumea announced a partnership with Paige, a leader in AI technology, to integrate AI-powered workflows into its FDA-cleared digital pathology platform. This collaboration aims to enhance diagnostic efficiency and accessibility in cancer care by streamlining workflows and improving diagnostic confidence.
2025-06
EINPresswire.com (via Lumea Digital Pathology)
The Digital Pathology Viewer You all Want is Now FDA Cleared
Lumea's Viewer+u2122 software has received FDA 510(k) clearance, establishing it as a centralized diagnostic hub for pathologists. This clearance signifies that Viewer+, part of Lumea's Digital Diagnostic Suiteu2122, meets high standards for safety and effectiveness for primary diagnosis in clinical settings.
2025-03
EINPresswire.com (via Lumea Digital Pathology)
Lumea and Voicebrook Announce Strategic Partnership to Advance Digital Pathology Workflows
Lumea and Voicebrook have formed a strategic partnership to integrate Voicebrook's VoiceOver PRO platform with Lumea's digital pathology ecosystem. This collaboration aims to enable practical, voice-enabled workflows across the pathology lab, from grossing to final sign-out, without disrupting established processes.
2026-01
Signify Research
Digital Pathology Market Update February 2026 | AI Partnerships, Investments & Platform Deployments
Lumea's Digital Pathology viewer has achieved IVDR certification in Europe, following its FDA clearance in March 2025. This certification positions Lumea to expand its regulated primary diagnosis deployments across Europe.
2026-03
EINPresswire.com (via Lumea Digital Pathology)
Lumea and Valar Labs Announce Partnership to Improve Bladder Cancer Treatment Decisions
Lumea and Valar Labs have partnered to integrate Valar Labs' Vesta tests into the Lumea digital pathology platform. This collaboration aims to provide urologists with an innovative tool to predict patient response to non-muscle-invasive bladder cancer (NMIBC) treatment.
2025-10
Lumea Digital Pathology
GI Alliance, the Leading GI Network, Selects Lumea's IMS
GI Alliance, a leading network of gastroenterology providers, has chosen Lumea's Viewer+u2122 technology for its digital pathology initiatives. This decision marks a significant step in GI Alliance's mission to adopt cutting-edge technologies to improve workflow across its national footprint.
2025-06
MarketersMEDIA Newsroom
Lumea Wins a 2025 Global Recognition Award for Advancing Cancer Diagnostics with Innovative Technology
Lumea received a 2025 Global Recognition Award for its contributions to cancer diagnostics through advanced technological solutions. The company's innovations aim to reduce waste, increase detection accuracy, and streamline workflows, impacting millions of specimen evaluations worldwide.
2025-07

Videos

Product demos, reviews, and walkthroughs for Lumea Digital Pathology.

View all on YouTube

Frequently Asked Questions

Lumea's platform is designed as a unified diagnostic suite that integrates image viewing, case management, AI results, and report generation, aiming to streamline the workflow and reduce the need for multiple systems and logins. It also offers seamless access to an AI marketplace, allowing chosen AI tools to support real-time sign-out within the viewer. Additionally, Lumea enables ordering and tracking of ancillary tests directly within the viewer, which can expedite results.
Lumea's platform has received FDA 510(k) clearance for primary clinical diagnosis, indicating its demonstrated equivalence to traditional methods. While Lumea provides compliance documentation, the practice remains responsible for the security of endpoint devices used to access the platform, including maintaining updated software, using strong passwords, and adhering to organizational device security policies. Labs must also perform internal validation studies, per CAP guidelines, to ensure diagnostic concordance between digital and glass slides.
Several other companies offer digital pathology solutions with AI integration. Some prominent alternatives include Roche Digital Pathology, Proscia, PathAI, Tribun Health/CaloPix, and Ibex Medical Analytics. These platforms often provide slide scanners, image analysis, and AI tools for various aspects of pathology, with some focusing on specific areas like cancer diagnosis or biomarker discovery.
The cost of implementing digital pathology with Lumea can vary based on the scale of operation and chosen technology, encompassing initial capital costs for hardware (scanners, monitors) and software, labor for training, ongoing maintenance, and data storage. Lumea suggests that labs implementing their full platform may recover their investment within three months through efficiency gains, reduced courier and storage costs, and fewer repeat procedures due to improved specimen quality. Long-term savings can also accumulate from reduced shipping, lower physical storage needs, and the ability to scale pathologist capacity.
Initial challenges may include the upfront capital expenditure for scanners and IT infrastructure, validation requirements to ensure diagnostic concordance, and managing the high data throughput of whole slide images. There can also be a temporary disruption to established workflows and a learning curve for staff. While digital pathology offers many benefits, its effectiveness depends on implementation quality, infrastructure readiness, tool selection, and adoption.
Lumea's platform has FDA 510(k) clearance for primary clinical diagnosis, demonstrating its equivalence to traditional methods. They also emphasize improving specimen integrity from the moment of biopsy with their tissue-handling technology (BxBoard, BxChip, BxCamera), which is designed to reduce fragmentation and preserve anatomic orientation, providing pathologists with better material for diagnosis. This pre-analytical focus aims to enhance diagnostic accuracy even before scanning.
Yes, Lumea Digital Pathology significantly enhances remote diagnostics and teleconsultation. Pathologists are no longer tied to a single physical location and can diagnose from any validated location with a sufficient monitor and internet connection. This allows for instant access to cases, facilitates second opinions from subspecialty experts without shipping physical slides, and enables real-time workload balancing across multiple sites.

Related Tools

OCTA
OCTA
Clinical Decision Support & Reference
OCTA Flow is an AI-powered platform that assists ophthalmologists in analyzing Optical Coherence Tomography Angiography (OCTA) scans to enhance diagnostic accuracy and efficiency.
Starts from $0/month (free plan) to $2,999/month (lead plan) for octa core.
Elsevier
Elsevier
Clinical Decision Support & Reference
ClinicalKey AI is a clinical decision support tool that uses artificial intelligence to provide physicians with rapid access to evidence-based medical information.
Paid subscription, with individual and institutional plans.
EvidenceMD
EvidenceMD
Clinical Decision Support & Reference
EvidenceMD is an AI-powered clinical decision support platform that provides physicians with rapid access to current and relevant medical evidence for informed decision-making.
Free, individual, max, enterprise
FAITH project
AI Agent
Clinical Decision Support & Reference
The FAITH project focuses on Federated Artificial Intelligence for Trusted Healthcare, aiming to develop secure and privacy-preserving AI solutions for healthcare, including potential applications for physician directories.
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
Prof. Valmed
Prof. Valmed - validated medical information GmbH
Clinical Decision Support & Reference
Prof. Valmed is Europe's first CE Class IIb certified AI-supported medical co-pilot, providing healthcare professionals with validated, evidence-based medical information through an innovative AI platform.
Paid subscription

See all Clinical Decision Support & Reference tools →

More from Lumea

Lumea Viewer+
Lumea
Clinical Decision Support & Reference
Lumea Viewer+ is an FDA-cleared digital pathology viewer and diagnostic hub for pathologists, offering AI integration, lightning-fast image rendering, and comprehensive case management within a unified workflow.
Contact vendor
Viewer+
Lumea
Clinical Decision Support & Reference
Lumea's Viewer+ is an FDA-cleared digital pathology viewer with AI-driven workflows for primary diagnosis in clinical settings, supporting various specialties.
Contact for pricing

View company profile →

Suggest an Edit → | Last Verified: 2026-09-09 | First Added: 2026-09-09
AI Tool Finder
AI-powered search. Results may not be comprehensive.